Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Loch T. Urologic imaging for localized prostate cancer 2007. World J Urol. 2007;25:121.
Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology. 2007;243:28.
Wijkstra H, Wink MH, de la Rosette JJ. Contrast specific imaging in the detection and localization of prostate cancer. World J Urol. 2004;22:346.
Halpern EJ. Contrast-enhanced ultrasound imaging of prostate cancer. Rev Urol. 2006;8 Suppl 1:S29.
Pelzer A, Bektic J, Berger AP, Pallwein L, Halpern EJ, Horninger W, et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol. 2005;173:1926.
Remzi M, Dobrovits M, Reissigl A, Ravery V, Waldert M, Wiunig C, et al. European Society for Oncological Urology (ESOU): Can power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy? Eur Urol. 2004;46:451.
Cheng S, Rifkin MD. Color Doppler imaging of the prostate: important adjunct to endorectal ultrasound of the prostate in the diagnosis of prostate cancer. Ultrasound Q. 2001;17:185.
Drudi FM, Giovagnorio F, Carbone A, Ricci P, Petta S, Cantisani V, et al. Transrectal colour Doppler contrast sonography in the diagnosis of local recurrence after radical prostatectomy–comparison with MRI. Ultraschall Med. 2006;27:146.
Tamsel S, Killi R, Apaydin E, Hekimgil M, Demirpolat G. The potential value of power Doppler ultrasound imaging compared with grey-scale ultrasound findings in the diagnosis of local recurrence after radical prostatectomy. Clin Radiol. 2006;61:325.
Yi A, Kim JK, Park SH, Kim KW, Kim HS, Kim JH, et al. Contrast-enhanced sonography for prostate cancer detection in patients with indeterminate clinical findings. AJR. 2006;186:1431.
Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer. 2005;104:2373.
Yves EP, Gomella LG, Halpern EJ. Effect of dutasteride therapy on Doppler evaluation of the prostate: preliminary results. Radiology. 2005;237:197.
Frey H. Realtime elastography. A new ultrasound procedure for the reconstruction of tissue elasticity. Radiologe. 2003;43(10):850–5.
König K, Scheipers U, Pesavento A, Lorenz A, Ermert H, Senge T. Initial experiences with real-time elastography guided biopsies of the prostate. J Urol. 2005;174(1):115–7.
Cochlin DL, Ganatra RH, Griffiths DF. Elastography in the detection of prostatic cancer. Clin Radiol. 2002;57(11):1014–20.
Cruz M, Tsuda K, Narumi Y, et al. Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol. 2002;12:357–65.
Kirkham APS, Emberton M, Allen C. How good is MRI at detection and characterising cancer within the prostate? Eur Urol. 2006;50:1163–7.
Qayyum A, Cookley FV, Lu Y, et al. Organ confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol. 2004;183:1079–83.
Schlemmer HP, Merkle J, Grobholz R, et al. Can preoperative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol. 2004;14:309–14.
Ito H, Kamoi K, Yokoyama K, Yamada K, Nishimura T. Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound. Br J Radiol. 2003;76:617–24.
Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate. 2005;62:40–7.
Ikonen S, Karkkainen P, Kivisaari L, et al. Magnetic resonance imaging of clinically localized prostate cancer. J Urol. 1998;159:915–9.
Vilanova JC, Barceló J. Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging. Abdom Imaging. 2007; (Epub ahead of print).
Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging – clinicopathologic study. Radiology. 1999;213:473–80.
Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of prostate biopsy, magnetic resonance imaging, and magnetic resonance spectrocopic imaging with step section histology. J Urol. 2000;164:400–4.
Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804–14.
Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002;16:451–63.
Sala E, Akin O, Moskowitz CS, et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology. 2006;238:929–37.
Cornud F, Flam T, Chauveinc L, et al. Extraprostatic spread of clinically localized prostate cancer : factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology. 2002;224:203–10.
Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardina PT. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology. 2004;232:140–6.
Wolf JS JR, Cher M, Dall’era M, Presti JC, Hricak H,Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995;153:993–9.
Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol. 2005;48:546–51.
Saokar A, Braschi M, Harinsinghani MG. Lymphotrophic nanoparticle enhanced MR imaging (LNMRI) for lymph node imaging. Abdom Imaging. 2006;31:660–7.
Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles – initial clinical experience. Radiology. 1998;207:799–808.
Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph node metastasis in prostate cancer. N Engl J Med. 2003;348:2491–9.
Heidenreich A, Varga Z, v Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastases. J Urol.2002;167:1681–6.
Bader P, Burkhardt FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol. 2002;168:514–8.
Wawroschek F, Vogt H, Wengenmair H, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int. 2003;70:303–10.
Palmer E, Henrikson K, McKusik K, Strauss HW, Hochberg F. Pain as an indicator of bone metastasis. Acta Radiol. 1988;29:445–9.
Tombal B, Rezazadeh A, Therasse P, van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate. 2005;65:178–87.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high risk prostate cancer: 99m Tc-MDP planar bone scintigraphy, single-and multi field of view SPECT, 18F-flouride PET, and 18F-flouride PET/CT. J Nucl Med. 2006;47:287–97.
Delpassand ES, Garcia JR, Bhadkamar V, Podoloff DA. Value of SPECT imaging of the thoracolumbar spine in cancer patients. Clin Nucl Med. 1995;20:1047–51.
Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344–50.
Parent EE, Dence CS, Sharp TL, et al. Synthesis and biological evaluation of a flourine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]flouro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imide. Nucl Med Biol. 2006;33:615–24.
Lee KC, Sud S, Meyer CR, et al. An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone. Cancer Res. 2007;67:3524–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag London Limited
About this chapter
Cite this chapter
Heidenreich, A. (2009). Considerations: Imaging in Prostate Cancer. In: de la Rosette, J.J., Manyak, M.J., Harisinghani, M.G., Wijkstra, H. (eds) Imaging in Oncological Urology. Springer, London. https://doi.org/10.1007/978-1-84628-759-6_24
Download citation
DOI: https://doi.org/10.1007/978-1-84628-759-6_24
Publisher Name: Springer, London
Print ISBN: 978-1-84628-514-1
Online ISBN: 978-1-84628-759-6
eBook Packages: MedicineMedicine (R0)